Alogliptin - effective and safe decision in the management of type 2 diabetes mellitus

Cover Page

Cite item

Full Text

Abstract

The present article covers the features of alogliptin (Vipidia) and its facilities in the management of type 2 diabetes mellitus from the perspective of clinically-based patient-centered approach.

About the authors

N. A Petunina

I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation

Email: napetunina@mail.ru
д-р мед. наук, проф., зав. каф. эндокринологии ИПО ГБОУ ВПО Первый МГМУ им. И.М.Сеченова 119991, Russian Federation, Moscow, ul. Trubet- skaia, d. 8, str. 2

A. L Terekhova

I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation

ассистент каф. эндокринологии ИПО ГБОУ ВПО Первый МГМУ им. И.М.Сеченова 119991, Russian Federation, Moscow, ul. Trubet- skaia, d. 8, str. 2

References

  1. International Diabetes Federation, 2013. IDF Diabetes Atlas, Sixth edition. www.idf.org/diabetesatlas
  2. American Diabetes Association, Standards of Medical Care in Diabetes - 2015. Diabetes Care 2015; 38 (Suppl. 1): 1-94.
  3. Дедов И.И., Шестакова М.В. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 6-е изд., 2013.
  4. Management of hyperglycemia in type 2 diabetes, 2015: a patient - centered approach update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38: 140-9. doi: 10.2337/dc14-2441.
  5. Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: similarities and differences. J Diabetes Investig 2010; 1: 8-23.
  6. Cox M.E, Rowell J, Corsino L, Green J.B. Dipeptidyl peptidase-4 inhibitors in the management of type diabetes: safety, tolerability and efficacy. Drug Health Patient Saf 2010; 2: 7-19.
  7. Kutoh E, Ukai Y. Alogliptin as an initial therapy in patients with newly diagnosed, drug naхve type 2 diabetes: a randomized, control trial. Endocrine 2012; 41 (3): 435-41.
  8. Seino Y, Fujita T, Hiroi S et al. Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double - blind, dose - ranging comparison with placebo, followed by a long - term extension study. Curr Med Res Opin 2011; 27(9): 1781-92.
  9. De Fronzo R.A, Fleck P.R, Wilson C.A, Mekki Q. Alogliptin Study 010 Group Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double - blind, placebocontrolled study. Diabetes Care 2008; 31 (12): 2315-7.
  10. Rosenstock J, Inzucchi S.E, Seufert J et al. Initial combination therapy with alogliptin and pioglitazone in drug - naпve patients with type 2 diabetes. Diabetes Care 2010; 33(11): 2406-8.
  11. Pratley R, Wilson C, Fleck P. Alogliptin plus metformin combination therapy vs. alogliptin or metformin monotherapy for type 2 DM (abstract). Presented at 48th Annual Meeting of the European Association for the Study of Diabetes; Berlin, Germany.October 2012.
  12. Seino Y, Miyata Y, Hiroi S et al. Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double - blind, placebo - controlled trial with an open - label, long - term extension study. Diabetes Obes Metab 2012; 14 (10): 927-36.
  13. De Fronzo R.A, Burant C.F, Fleck P et al. Efficacy and olerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin - treated patients with type 2 diabetes. J Clin Endocrinol Metab 2012; 97 (5): 1615-22.
  14. Nauck M.A, Ellis G.C, Fleck P.R, Wilson C.A, Mekki Q. Alogliptin Study 008 Group Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double - blind, placebo - controlled study.Int J Clin Pract 2009; 63 (1): 46-55.
  15. Del Prato S, Camisasca R, Craig Wilson et al. Durability of the Efficacy and safety of Alogliptin Compared to Glipizide over 2 Years When Used in Combination with Metformin.Poster 66-LB presented at the 73rd Scientific Sessions of the American Diabetes Association (ADA), Chicago, Illinois, June 21-25, 2013.
  16. Kaku K, Itayasu T, Hiroi S et al. Efficacy and safety of logliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double - blind, placebo - controlled trial with an open - label long - term extension study. Diabetes Obes Metab 2011; 13 (11): 1028-35.
  17. Pratley R.E, Reusch J.E, Fleck P.R et al. Alogliptin Study 009 Group Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double - blind, placebo - controlled study. Curr Med Res Opin 2009; 25 (10): 2361-71.
  18. Bosi E, Ellis G.C, Wilson C.A, Fleck P.R. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, doubleblind, active - controlled, parallel - group study. Diabetes Obes Metab 2011; 13 (12): 1088-96.
  19. Pratley R.E, Kipnes M.S, Fleck P.R et al. Alogliptin Study 007 Group Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab 2009; 11 (2):167-76.
  20. Seino Y, Fujita T, Hiroi S et al. Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double - blind, placebo - controlled trial with an open - label, long - term extension. Curr Med Res Opin 2011; 27 (Suppl. 3): 21-9.
  21. Rosenstock J, Rendell M.S, Gross J.L et al. Alogliptin added to insulin therapy in patients with type-2 diabetes reduces HbA1c without causing weight gain or increased hypoglycemia. Diabetes Obes Metab 2009; 11: 1145-52.
  22. Berhan A, Berhan Y. Efficacy of alogliptin in type 2 diabetes treatment: a meta - analysis of randomized double - blind controlled studies. BMC Endocrine Disorders 2013;13: 9. http://www.biomedcentral.com/1472-6823/13/9
  23. Capuano A, Sportiello L, Maiorino M, Rossi F et al. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy - focus on alogliptin. Drug Des Devel Ther 2013; 7:989-1001. doi: 10.2147/DDDT.S37647.
  24. Seino Y, Hiroi S, Hirayama K, Kaku K. Efficacy and safety of alogliptin added to sulfonylurea in Japanese patients with type 2 diabetes: a randomized, double - blind, placebo - controlled trial with an open - label, long - term extension study. J Diabetes Invest 2012; 3: 517-25.
  25. Gore M.O, Mc Guire D.K. The 10-year posttrial follow - up of the United Kingdom Prospective Diabetes Study (UKPDS): cardiovascular observations in context. Diab Vasc Dis Res 2009; 6: 53-5.
  26. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long - term complications in insulin - dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
  27. Desouza C.V, Bolli G.B, Fonseca V. Hypoglycemia, diabetes and cardiovascular events. Diabetes Care 2010; 33 (6): 1389-94.
  28. Rosenstock J, Wilson C, Fleck P. Alogliptin versus glipizide monotherapy in elderly type-2 diabetes mellitus patients with mild hyperglycemia: a prospective, double - blind, randomized, 1-year study. Diabetes Obes Metab 2013. doi: 10.1111/dom.12102.
  29. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular omplications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-13.
  30. Gregg E.W, Li Y, Wang J, Burrows N.R et al. Changes in diabetes - related complications in the United States, 1990-2010. N Engl J Med 2014; 370: 1514-23. doi: 10.1056/NEJMoa1310799.
  31. Food and Drug Administration, Center for Drug Evaluation and Research Guidance for industry: diabetes mellitus - evaluating cardiovascular risk in new antidiabetic therapies to treat type-2 diabetes. 2008 Dec; Available at: http://www.fda.gov /downloads/Drugs/Guidance ComplianceRegulatoryInformation/Guidances/UCM071627.pdf
  32. White W.B, Bakris G.L, Bergenstal R.M et al. EXamination of CArdiovascular OutcoMes with AlogliptIN versus Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. Am Heart J 2011; 162 (4): 620-6.
  33. Hall C. Alogliptin in patients with type 2 diabetes after acute coronary syndromes: heart failure outcomes and cardiovascular safety in heart failure patients. JACC 2014; 63 (12).
  34. Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta - analysis of randomized clinical trials. Diabetes Obes Metab 2013. doi: 10.1111/dom.12176.
  35. Vipidia: EPAR - Public assessment report. European Medicines Agency 2013. Available from: www.ema.europa.eu
  36. Christopher R, Karim A. Clinical pharmacology of alogliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of Type 2 diabetes. Expert Rev Clin Pharmacol 2009; 2: 589-600.
  37. Nesina (alogliptin), prescribing information. Deerfield, IL: Takeda Pharmaceuticals America, Inc., 2013.
  38. Инструкция по медицинскому применению препарата Випидия.

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies